Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Global Markets Direct’s, ‘Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Viamet Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Viamet Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the pipeline therapeutic landscape of Viamet Pharmaceuticals, Inc. - The report provides overview of Viamet Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Viamet Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Viamet Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Viamet Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Viamet Pharmaceuticals, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Viamet Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Candidiasis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Candidiasis Global Clinical Trials Review, H2, 2018" provides an overview of Candidiasis clinical trials scenario.This report provides top line data relating to the clinical trials on Candidiasis. Report...
Botulism - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H1 2019, provides an overview of the Botulism (Infectious Disease) pipeline landscape. Botulism is a rare but serious illness. The cause...
Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins,...
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018, provides an overview of the Human Papillomavirus (HPV) Associated...
221 pages •
By Asia Market Information & Development Company
• Jan 2019
China’s demand for Anti Dermatomycosis Skin Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.